Journal
JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 274, Issue 1-2, Pages 9-12Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2008.07.027
Keywords
Regulatory cell; TGF-beta; Antibody; Multiple sclerosis; Autoimmunity
Categories
Funding
- NIAID NIH HHS [R01 AI043458-10, R01 AI043458] Funding Source: Medline
Ask authors/readers for more resources
One of the major goals for the immunotherapy Of autoimmune diseases is the induction of regulatory T cells that mediate immunologic tolerance. Parenteral administration of anti-CD3 monoclonal antibody is an approved therapy for transplantation in humans and is effective in autoimmune diabetes. We have found that oral administration of anti-CD3 monoclonal antibody is biologically active in the gut and suppresses experimental autoimmune encephalomyelitis both prior to disease induction and at the height of disease. Oral anti-CD3 antibody acts by inducing a unique type of regulatory T cell characterized by latency-associated peptide (LAP) on its cell surface that functions in vivo and in vitro via TGF-beta dependent mechanism. Orally delivered antibody would not have side effects including cytokine release syndromes, thus oral anti-CD3 antibody is clinically applicable for chronic therapy. These findings identify a novel and powerful immunologic approach that is widely applicable for the treatment of human autoimmune conditions. (C) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available